The global autologous cell therapy market size is expected to reach USD 17.97 billion by 2030, based on a new report. The market is expected to expand at a CAGR of 22.20% from 2024 to 2030. The growing burden of diseases and disorders such as cancer, neurodegenerative disorders, cardiovascular disorders, autoimmune disorders, and orthopedics are the factors driving the demand for the market. Likewise, the reduced risk of autologous cell therapy rejection is one of the important factors for market growth as these therapies are developed from patient-derived cells and support the regeneration of the damaged tissues in the body. ![Autologous Cell Therapy Market]( "Autologous Cell Therapy Market")
During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.
In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.
This product will be delivered within 1-3 business days.
During the COVID-19 pandemic, the market has witnessed various challenges where patients were restricted to stay at home due to safety concerns. Some factors that affected the market growth are manufacturing hurdles and reduced patient inflow in hospitals. However, post-COVID-19 the market has witnessed the demand for the market with FDA clearance and all of the new advances in treating a wide range of disease indications.
In April 2020, Hope Biosciences, a clinical-stage biotechnology company announced the FDA clearance for a phase II clinical trial evaluating the efficacy & safety of HB-adMSCs (Hope Bioscience' autologous, adipose-derived mesenchymal stem cells), to offer immune support against COVID-19. In June 2020, Chiesi Group and Holostem Terapie Avanzate mentioned the agreement for the transfer of the business branch Holoclar. The Holoclar is an autologous stem cell therapy for patients with ocular surface burns. It aims to allow both companies to focus on the strategic objective and accelerate procedures access for rare diseases.
Autologous Cell Therapy Market Report Highlights
- The cancer segment dominated the market and accounted for a share of 29.9% in 2023. According to the American Cancer Society, it is anticipated that 1,958,310 new instances of cancer and 609,820 fatalities due to the disease.
- The bone marrow segment held the largest share of 29.9% in 2023. The bone marrow in autologous cell therapy has been successfully used to treat different diseases.
- The academics & research segment held the largest share of 39.05% in 2023 and is anticipated to grow rapidly from 2024 to 2030.
- North America autologous cell therapy market accounted for 36.68% share in 2023. The market is highly competitive since most of the major market players such as BrainStorm Cell Therapeutics and Bristol Myers Squibb operate in this region.
- Asia Pacific autologous cell therapy market is anticipated to witness fastest growth over the forecast period. owing to the rising burden of diseases, strong research activities in autologous cell therapies, the presence of a well-established biotechnology sector, developing healthcare facilities, and growing awareness for cell therapies.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Application
1.2.2. Source
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Application
1.2.2. Source
1.2.3. End Use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. Internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Application
2.2.2. Source outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.2.1. Application
2.2.2. Source outlook
2.2.3. End Use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Autologous Cell Therapy Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Numerous immunological advantages
3.2.1.2. Rise in the proportion of the geriatric population across the globe
3.2.1.3. Reduced risk of autologous cell therapy rejection
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Regulatory challenges
3.3. Autologous Cell Therapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Numerous immunological advantages
3.2.1.2. Rise in the proportion of the geriatric population across the globe
3.2.1.3. Reduced risk of autologous cell therapy rejection
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Regulatory challenges
3.3. Autologous Cell Therapy Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
Chapter 4. Autologous Cell Therapy Market: TApplication Estimates & Trend Analysis
4.1. Global Autologous Cell Therapy Market: Application Dashboard
4.2. Global Autologous Cell Therapy Market: Application Movement Analysis
4.3. Global Autologous Cell Therapy Market by Application, Revenue
4.4. Cancer
4.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Neurodegenerative disorders
4.5.1. Neurodegenerative disorders market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cardiovascular disorders
4.6.1. Cardiovascular disorders market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Autoimmune disorders
4.7.1. Autoimmune disorders market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Orthopedics
4.8.1. Orthopedics market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Wound healing
4.9.1. Wound healing market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
4.2. Global Autologous Cell Therapy Market: Application Movement Analysis
4.3. Global Autologous Cell Therapy Market by Application, Revenue
4.4. Cancer
4.4.1. Cancer market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Neurodegenerative disorders
4.5.1. Neurodegenerative disorders market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cardiovascular disorders
4.6.1. Cardiovascular disorders market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Autoimmune disorders
4.7.1. Autoimmune disorders market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Orthopedics
4.8.1. Orthopedics market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Wound healing
4.9.1. Wound healing market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Others
4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Autologous Cell Therapy Market: Source Estimates & Trend Analysis
5.1. Global Autologous Cell Therapy Market: Source Dashboard
5.2. Global Autologous Cell Therapy Market: Source Movement Analysis
5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Source, Revenue (USD Million)
5.4. Bone Marrow
5.4.1. Bone marrow market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Epidermis
5.5.1. Epidermis market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Mesenchymal stem cells
5.6.1. Mesenchymal stem cells market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Haematopoietic stem cells
5.7.1. Haematopoietic stem cells market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Chondrocytes
5.8.1. Chondrocytes market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
5.2. Global Autologous Cell Therapy Market: Source Movement Analysis
5.3. Global Autologous Cell Therapy Market Estimates and Forecasts, By Source, Revenue (USD Million)
5.4. Bone Marrow
5.4.1. Bone marrow market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Epidermis
5.5.1. Epidermis market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Mesenchymal stem cells
5.6.1. Mesenchymal stem cells market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Haematopoietic stem cells
5.7.1. Haematopoietic stem cells market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Chondrocytes
5.8.1. Chondrocytes market estimates and forecasts 2018 to 2030 (USD Million)
5.9. Others
5.9.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Autologous Cell Therapy Market: End Use Estimates & Trend Analysis
6.1. Global Autologous Cell Therapy Market: End Use Dashboard
6.2. Global Autologous Cell Therapy Market: End Use Movement Analysis
6.3. Global Autologous Cell Therapy Market Estimates and Forecasts, by End Use, Revenue (USD Million)
6.4. Hospitals & Clinics
6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Ambulatory Centers
6.5.1. Ambulatory centers market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Academics & Research
6.6.1. Academics & research market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
6.2. Global Autologous Cell Therapy Market: End Use Movement Analysis
6.3. Global Autologous Cell Therapy Market Estimates and Forecasts, by End Use, Revenue (USD Million)
6.4. Hospitals & Clinics
6.4.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Ambulatory Centers
6.5.1. Ambulatory centers market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Academics & Research
6.6.1. Academics & research market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Autologous Cell Therapy Market: Regional Estimates & Trend Analysis by Application, Source, and End Use
7.1. Regional Dashboard
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.2. Vendor Landscape
8.2.1. List of key distributors and channel partners
8.2.2. Key customers
8.2.3. Key company market share analysis, 2023
8.2.4. BrainStorm Cell Therapeutics
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Holostem Terapie Avanzate S.R.L
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Pharmicell Co. Inc
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Opexa Therapeutics
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Caladrius Biosciences Inc
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. U.S. Stem Cell Inc
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Lonza
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. Bristol Myers Squibb
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Novartis AG.
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Autolus therapeutics
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. Tego Science
8.2.14.1. Company overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives
8.2.15. Corning Incorporated
8.2.15.1. Company overview
8.2.15.2. Financial performance
8.2.15.3. Product benchmarking
8.2.15.4. Strategic initiatives
8.2.16. Bio Elpida
8.2.16.1. Company overview
8.2.16.2. Financial performance
8.2.16.3. Product benchmarking
8.2.16.4. Strategic initiatives
8.2.17. Vericel Corporation
8.2.17.1. Company overview
8.2.17.2. Financial performance
8.2.17.3. Product benchmarking
8.2.17.4. Strategic initiatives
8.2.18. Catalent, Inc
8.2.18.1. Company overview
8.2.18.2. Financial performance
8.2.18.3. Product benchmarking
8.2.18.4. Strategic initiatives
8.2.19. Sartorius AG
8.2.19.1. Company overview
8.2.19.2. Financial performance
8.2.19.3. Product benchmarking
8.2.19.4. Strategic initiatives
8.2. Vendor Landscape
8.2.1. List of key distributors and channel partners
8.2.2. Key customers
8.2.3. Key company market share analysis, 2023
8.2.4. BrainStorm Cell Therapeutics
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Holostem Terapie Avanzate S.R.L
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. Pharmicell Co. Inc
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Opexa Therapeutics
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Caladrius Biosciences Inc
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. U.S. Stem Cell Inc
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Lonza
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
8.2.11. Bristol Myers Squibb
8.2.11.1. Company overview
8.2.11.2. Financial performance
8.2.11.3. Product benchmarking
8.2.11.4. Strategic initiatives
8.2.12. Novartis AG.
8.2.12.1. Company overview
8.2.12.2. Financial performance
8.2.12.3. Product benchmarking
8.2.12.4. Strategic initiatives
8.2.13. Autolus therapeutics
8.2.13.1. Company overview
8.2.13.2. Financial performance
8.2.13.3. Product benchmarking
8.2.13.4. Strategic initiatives
8.2.14. Tego Science
8.2.14.1. Company overview
8.2.14.2. Financial performance
8.2.14.3. Product benchmarking
8.2.14.4. Strategic initiatives
8.2.15. Corning Incorporated
8.2.15.1. Company overview
8.2.15.2. Financial performance
8.2.15.3. Product benchmarking
8.2.15.4. Strategic initiatives
8.2.16. Bio Elpida
8.2.16.1. Company overview
8.2.16.2. Financial performance
8.2.16.3. Product benchmarking
8.2.16.4. Strategic initiatives
8.2.17. Vericel Corporation
8.2.17.1. Company overview
8.2.17.2. Financial performance
8.2.17.3. Product benchmarking
8.2.17.4. Strategic initiatives
8.2.18. Catalent, Inc
8.2.18.1. Company overview
8.2.18.2. Financial performance
8.2.18.3. Product benchmarking
8.2.18.4. Strategic initiatives
8.2.19. Sartorius AG
8.2.19.1. Company overview
8.2.19.2. Financial performance
8.2.19.3. Product benchmarking
8.2.19.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 3 North America autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 4 North America autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 5 North America autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 7 U.S. autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 8 U.S. autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 9 Canada autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 10 Canada autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 11 Canada autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 12 Mexico autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 13 Mexico autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 14 Mexico autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 15 Europe autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 16 Europe autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 17 Europe autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 18 Europe autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 19 Germany autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 20 Germany autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 21 Germany autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 22 UK autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 23 UK autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 24 UK autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 25 France autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 26 France autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 27 France autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 28 Italy autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 29 Italy autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 30 Italy autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 31 Spain autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 32 Spain autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 33 Spain autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 34 Denmark autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 35 Denmark autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 36 Denmark autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 37 Sweden autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 38 Sweden autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 39 Sweden autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 40 Norway autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 41 Norway autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 42 Norway autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 45 Asia Pacific autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 46 Aisa Pacific autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 47 China autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 48 China autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 49 China autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 50 Japan autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 51 Japan autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 52 Japan autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 53 India autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 54 India autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 55 India autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 56 South Korea autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 57 South Korea autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 58 South Korea autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 59 Australia autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 60 Australia autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 61 Australia autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 62 Thailand autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 63 Thailand autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 64 Thailand autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 65 Latin America autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 67 Latin America autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 68 Latin America autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 69 Brazil autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 70 Brazil autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 71 Brazil autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 72 Argentina autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 73 Argentina autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 74 Argentina autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 75 MEA autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 76 MEA autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 77 MEA autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 78 MEA autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 79 South Africa autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 80 South Africa autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 81 South Africa autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 85 UAE autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 86 UAE autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 87 UAE autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 88 Kuwait autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 89 Kuwait autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 90 Kuwait autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 2 North America autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 3 North America autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 4 North America autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 5 North America autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 6 U.S. autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 7 U.S. autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 8 U.S. autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 9 Canada autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 10 Canada autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 11 Canada autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 12 Mexico autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 13 Mexico autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 14 Mexico autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 15 Europe autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 16 Europe autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 17 Europe autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 18 Europe autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 19 Germany autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 20 Germany autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 21 Germany autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 22 UK autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 23 UK autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 24 UK autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 25 France autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 26 France autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 27 France autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 28 Italy autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 29 Italy autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 30 Italy autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 31 Spain autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 32 Spain autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 33 Spain autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 34 Denmark autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 35 Denmark autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 36 Denmark autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 37 Sweden autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 38 Sweden autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 39 Sweden autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 40 Norway autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 41 Norway autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 42 Norway autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 43 Asia Pacific autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 44 Asia Pacific autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 45 Asia Pacific autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 46 Aisa Pacific autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 47 China autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 48 China autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 49 China autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 50 Japan autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 51 Japan autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 52 Japan autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 53 India autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 54 India autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 55 India autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 56 South Korea autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 57 South Korea autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 58 South Korea autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 59 Australia autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 60 Australia autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 61 Australia autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 62 Thailand autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 63 Thailand autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 64 Thailand autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 65 Latin America autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 66 Latin America autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 67 Latin America autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 68 Latin America autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 69 Brazil autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 70 Brazil autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 71 Brazil autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 72 Argentina autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 73 Argentina autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 74 Argentina autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 75 MEA autologous cell therapy market, by region, 2018 - 2030 (USD Million)
Table 76 MEA autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 77 MEA autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 78 MEA autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 79 South Africa autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 80 South Africa autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 81 South Africa autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 82 Saudi Arabia autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 83 Saudi Arabia autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 84 Saudi Arabia autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 85 UAE autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 86 UAE autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 87 UAE autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
Table 88 Kuwait autologous cell therapy market, by application, 2018 - 2030 (USD Million)
Table 89 Kuwait autologous cell therapy market, by source, 2018 - 2030 (USD Million)
Table 90 Kuwait autologous cell therapy market, by end use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Autologous cell therapy market: market outlook
Fig. 14 Autologous cell therapy competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Autologous cell therapy market driver impact
Fig. 18 Autologous cell therapy market restraint impact
Fig. 19 Autologous cell therapy market: Application movement analysis
Fig. 20 Autologous cell therapy market: Application outlook and key takeaways
Fig. 21 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Neurodegenerative disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Autoimmune disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Orthopedics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Wound healing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Autologous cell therapy market: Source movement analysis
Fig. 29 Autologous cell therapy market: Source outlook and key takeaways
Fig. 30 Bone marrow market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Epidermis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Mesenchymal stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Haematopoietic stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Chondrocytes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Autologous cell therapy market: End use movement analysis
Fig. 37 Autologous cell therapy market: End use outlook and key takeaways
Fig. 38 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Ambulatory centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Academics & research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Global autologous cell therapy market: Regional movement analysis
Fig. 43 Global autologous cell therapy market: Regional outlook and key takeaways
Fig. 44 Global autologous cell therapy market share and leading players
Fig. 45 North America, by country
Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 U.S. key country dynamics
Fig. 48 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Canada key country dynamics
Fig. 50 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Mexico key country dynamics
Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 UK key country dynamics
Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Germany key country dynamics
Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 France key country dynamics
Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Italy key country dynamics
Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Spain key country dynamics
Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Denmark key country dynamics
Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Sweden key country dynamics
Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Norway key country dynamics
Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 China key country dynamics
Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Japan key country dynamics
Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 India key country dynamics
Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Thailand key country dynamics
Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 South Korea key country dynamics
Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Australia key country dynamics
Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Brazil key country dynamics
Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Argentina key country dynamics
Fig. 87 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 South Africa key country dynamics
Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Saudi Arabia key country dynamics
Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 UAE key country dynamics
Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Kuwait key country dynamics
Fig. 96 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Market share of key market players- autologous cell therapy market
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Autologous cell therapy market: market outlook
Fig. 14 Autologous cell therapy competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Autologous cell therapy market driver impact
Fig. 18 Autologous cell therapy market restraint impact
Fig. 19 Autologous cell therapy market: Application movement analysis
Fig. 20 Autologous cell therapy market: Application outlook and key takeaways
Fig. 21 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Neurodegenerative disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Cardiovascular disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Autoimmune disorders market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Orthopedics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Wound healing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Autologous cell therapy market: Source movement analysis
Fig. 29 Autologous cell therapy market: Source outlook and key takeaways
Fig. 30 Bone marrow market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 31 Epidermis market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 32 Mesenchymal stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Haematopoietic stem cells market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Chondrocytes market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Autologous cell therapy market: End use movement analysis
Fig. 37 Autologous cell therapy market: End use outlook and key takeaways
Fig. 38 Hospitals & clinics market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Ambulatory centers market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 Academics & research market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 41 Others market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 42 Global autologous cell therapy market: Regional movement analysis
Fig. 43 Global autologous cell therapy market: Regional outlook and key takeaways
Fig. 44 Global autologous cell therapy market share and leading players
Fig. 45 North America, by country
Fig. 46 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 U.S. key country dynamics
Fig. 48 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Canada key country dynamics
Fig. 50 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Mexico key country dynamics
Fig. 52 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 UK key country dynamics
Fig. 55 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 56 Germany key country dynamics
Fig. 57 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 France key country dynamics
Fig. 59 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Italy key country dynamics
Fig. 61 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Spain key country dynamics
Fig. 63 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Denmark key country dynamics
Fig. 65 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 66 Sweden key country dynamics
Fig. 67 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 68 Norway key country dynamics
Fig. 69 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 70 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 China key country dynamics
Fig. 72 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Japan key country dynamics
Fig. 74 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 India key country dynamics
Fig. 76 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Thailand key country dynamics
Fig. 78 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 South Korea key country dynamics
Fig. 80 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Australia key country dynamics
Fig. 82 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 83 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Brazil key country dynamics
Fig. 85 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Argentina key country dynamics
Fig. 87 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 89 South Africa key country dynamics
Fig. 90 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 91 Saudi Arabia key country dynamics
Fig. 92 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 93 UAE key country dynamics
Fig. 94 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 95 Kuwait key country dynamics
Fig. 96 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 97 Market share of key market players- autologous cell therapy market
Companies Mentioned
- BrainStorm Cell Therapeutics
- Holostem Terapie Avanzate S.R.L
- Pharmicell Co. Inc
- Opexa Therapeutics
- Caladrius Biosciences Inc
- U.S. Stem Cell Inc
- Lonza
- Bristol Myers Squibb
- Novartis AG.
- Autolus therapeutics
- Tego Science
- Corning Incorporated
- Bio Elpida
- Vericel Corporation
- Catalent, Inc
- Sartorius AG
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 85 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 4.32 Billion |
| Forecasted Market Value ( USD | $ 17.97 Billion |
| Compound Annual Growth Rate | 22.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
